NCT01058707View on ClinicalTrials.gov

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

January 4, 2010

Primary Completion Date

February 7, 2019

Study Completion Date

February 7, 2019

Conditions
Advanced Solid Malignancies
Interventions
DRUG

MLN0128

MLN0128 capsules

Trial Locations (16)

Unknown

Scottsdale

Los Angeles

Miami

Sarasota

Indianapolis

Boston

Ann Arbor

Detroit

Buffalo

New York

Cleveland

Oklahoma City

Philadelphia

Nashville

Barcelona

Valencia

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01058707 - Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies | Biotech Hunter | Biotech Hunter